Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program ivps42020-08-06T15:11:37-04:00August 6th, 2020|Press Release| Read More
Achieve Life Sciences Announces Pricing of $6.5 Million Public Offering ivps42020-08-04T00:09:12-04:00August 4th, 2020|Press Release| Read More
Achieve Life Sciences Announces Proposed Public Offering ivps42020-08-03T16:01:34-04:00August 3rd, 2020|Press Release| Read More
Achieve Announces Patent Granted in the U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications ivps42020-07-30T20:07:09-04:00July 31st, 2020|Press Release| Read More
Achieve Life Sciences to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020 ivps42020-07-20T16:17:59-04:00July 28th, 2020|Press Release| Read More
Achieve Life Sciences Announces Pricing of $6 Million Registered Direct Offering ivps42020-06-29T07:14:01-04:00June 29th, 2020|Press Release| Read More
Achieve Announces Successful Results from the Investigator-Initiated RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix (varenicline) as a Treatment to Quit Smoking ivps42020-06-29T07:14:32-04:00June 29th, 2020|Press Release| Read More
Achieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program ivps42020-05-13T16:50:34-04:00May 14th, 2020|Press Release| Read More
Achieve Life Sciences to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 14, 2020 ivps42020-05-04T15:22:00-04:00May 5th, 2020|Press Release| Read More
Achieve Life Sciences Announces Private Placement of $1.9 Million ivps42020-04-30T15:51:08-04:00April 30th, 2020|Press Release| Read More